Detalles de la búsqueda
1.
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
Cardiovasc Diabetol
; 23(1): 104, 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38504284
2.
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Diabetes Obes Metab
; 24(9): 1788-1799, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35546450
3.
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Diabetes Obes Metab
; 21(9): 2152-2162, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31144431
4.
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
Diabetes Obes Metab
; 21(11): 2429-2439, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31264757
5.
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Diabetes Obes Metab
; 21(11): 2450-2458, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31282028
6.
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Diabetes Obes Metab
; 20(11): 2598-2607, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29947099
7.
Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial.
Health Qual Life Outcomes
; 13: 77, 2015 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26055391
8.
Normal values for intima-media thickness of the common carotid artery--an update following a novel risk factor profiling.
Vasa
; 44(6): 444-50, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26515221
9.
Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.
Cardiovasc Endocrinol Metab
; 12(1): e0279, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36777095
10.
Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.
Exp Clin Endocrinol Diabetes
; 131(4): 205-215, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36599459
11.
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.
BMJ Open Diabetes Res Care
; 10(1)2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042751
12.
Cardiovascular outcome trials in obesity: A review.
Obes Rev
; 22(1): e13112, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32893459
13.
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.
Drugs
; 81(12): 1373-1379, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34302636
14.
'Knowing what Matters in diabetes: Healthier below 7': results of the campaign's first 10 years (part 2), participants without known diabetes history.
Cardiovasc Endocrinol
; 6(1): 48-54, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28392974
15.
[Insulin therapy: as late as possible]. / Insulintherapie bei Typ-2-Diabetes--so spät wie möglich!
Dtsch Med Wochenschr
; 141(8): 579-80, 2016 Apr.
Artículo
en Alemán
| MEDLINE | ID: mdl-27078250
16.
Usability Evaluation of a Blood Glucose Monitoring System With a Spill-Resistant Vial, Easier Strip Handling, and Connectivity to a Mobile App: Improvement of Patient Convenience and Satisfaction.
J Diabetes Sci Technol
; 10(5): 1136-41, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27390222
17.
'Knowing what matters in diabetes: healthier below 7': results of the campaign's first 10 years (part 1): participants with known type 2 diabetes.
Cardiovasc Endocrinol
; 5(1): 14-20, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28392972
18.
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
J Hypertens
; 34(6): 1140-50, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26855018
19.
The future of cardiovascular and metabolic medical practice: evidence-based winds of change.
Cardiovasc Endocrinol Metab
; 9(3): 64-65, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32803136
20.
Exercise prescription in patients with type 2 diabetes and coronary heart disease: could less be more?
Cardiovasc Endocrinol Metab
; 9(1): 1-2, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32104784